Associate Director, HEOR Analytics

The role

This person will design and execute real-world evidence analyses using large-scale healthcare datasets. They will lead the development of study protocols, statistical analysis plans, and study reports to support evidence generation priorities.

What you will do

• Lead development of analytical strategies supporting HEOR, Medical Affairs, and market access
• Design methodologies including statistical approaches and advanced analytics
• Apply epidemiologic and statistical methodologies to address bias and confounding
• Contribute to protocol development, database specifications, and statistical analysis plans
• Perform and oversee statistical programming and analysis using SAS, R, Python, and SQL
• Develop and validate analysis-ready datasets and analytic workflows
• Lead cohort identification using clinical coding systems
• Support data acquisition strategy by identifying real-world data sources
• Translate analytical results into actionable insights for non-technical stakeholders
• Manage and oversee external vendors and CROs

Required qualifications

• PhD or Master’s degree in Biostatistics, Epidemiology, Health Economics, Data Science, or related quantitative field
• 5+ years of experience conducting analyses using real-world healthcare data (claims, EHR/EMR, registries)
• Ability to work on site Monday, Tuesday & Thursday
• Experience designing and executing observational and retrospective studies
• Track record of generating real-world evidence to support publications or market access
• Strong programming skills in SAS, R, Python, and/or SQL
• Expertise in statistical methods (e.g., regression, survival analysis, causal inference)
• Hands-on experience with large healthcare databases and data structures
• Experience with cohort construction and data transformation

Benefits

• Annual bonus
• Significant equity
• Generous benefits package

About the company

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. Their neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine.